Oragenics Says NYSE American Approves Compliance Plan And Grant Extension Through February 2028

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, today announced that NYSE Regulation has accepted the Company’s compliance plan (the "Plan") and granted an extension through February 25, 2028 to regain compliance with NYSE American continued listing standards. 

The acceptance of the Company’s Plan enables Oragenics to maintain its NYSE American listing while executing initiatives designed to strengthen its financial position and support long-term shareholder value creation. The Company will continue trading on NYSE American throughout the compliance period, subject to meeting plan milestones and ongoing review requirements.